Article
Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Chemico-biological interactions - 25 Sept 2017
Divakar S, Saravanan K, Karthikeyan P, Elancheran R, Kabilan S, Balasubramanian K K, Devi Rajlakshmi, Kotoky J, Ramanathan M
Abstract excerpt
Treatment by androgen receptor (AR) antagonists is one of the regimens for prostate cancer. The prolonged treatment with AR antagonist leads to the expression of point mutation in the ligand binding domain of the AR. This point mutation causes resistance to AR antagonist by converting them into an agonist. The T887A mutated AR was frequently expressed in androgen independent prostate cancer (AIPC) patients....
Topics
- Amines
- Androgen Receptor Antagonists
- Antineoplastic Agents
- Apoptosis
- Binding Sites
- Caspase 3
- Cell Line, Tumor
- Cell Proliferation
- Humans
- Imines
- Male
- Microscopy, Fluorescence
- Molecular Docking Simulation